Alopecia Areata Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Alopecia Areata Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Alopecia Areata pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Alopecia Areata Pipeline @ https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Alopecia Areata Pipeline Report

* On June 01, 2026- Epibiotech initiated a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia. In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration. In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement, clinical photography, investigator assessment, expert panel assessment, and subject self-assessment during a follow-up period of up to 48 weeks.
* On May 22, 2026- Eli Lilly and Company conducted a phase 2 study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
* On May 20, 2026- Almirall, S.A. announced a phase 2 study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
* DelveInsight's Alopecia Areata pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata treatment.
* The leading Alopecia Areata Companies such as Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
* Promising Alopecia Areata Pipeline Therapies such as PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.

Stay ahead with the most recent pipeline outlook for Alopecia Areata @ Alopecia Areata Treatment Drugs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alopecia Areata Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.

Alopecia Areata Emerging Drugs

* Deuruxolitinib: Concert Pharmaceuticals

Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

* EQ101: Equillium

EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

* MAX 40070: Maxinovel Pharmaceuticals

MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

The Alopecia Areata Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
* Alopecia Areata Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market

Explore groundbreaking therapies and clinical trials in the Alopecia Areata Pipeline @ New Alopecia Areata Drugs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alopecia Areata Companies

Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.

Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Alopecia Areata Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Alopecia Areata Market Drivers and Barriers [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Alopecia Areata Pipeline Report

* Coverage- Global
* Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
* Alopecia Areata Pipeline Therapies- PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.
* Alopecia Areata Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Alopecia Areata Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Alopecia Areata Therapies and clinical trials @ Alopecia Areata Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Alopecia Areata: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Alopecia Areata- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Deuruxolitinib: Concert Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EQ101: Equillium
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MAX 40070: Maxinovel Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Alopecia Areata Key Companies
* Alopecia Areata Key Products
* Alopecia Areata- Unmet Needs
* Alopecia Areata- Market Drivers and Barriers
* Alopecia Areata- Future Perspectives and Conclusion
* Alopecia Areata Analyst Views
* Alopecia Areata Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alopecia-areata-pipeline-gains-momentum-18-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.